A
Albiruni Ryan Abdul Razak
Researcher at Princess Margaret Cancer Centre
Publications - 253
Citations - 7154
Albiruni Ryan Abdul Razak is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 39, co-authored 195 publications receiving 5045 citations. Previous affiliations of Albiruni Ryan Abdul Razak include Harvard University & University Health Network.
Papers
More filters
Journal ArticleDOI
Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib
Filip Janku,Albiruni Ryan Abdul Razak,Ping Chi,Michael Heinrich,Margaret von Mehren,Robin L. Jones,Kristen N. Ganjoo,Jonathan C. Trent,Hans Gelderblom,Neeta Somaiah,Simin Hu,Oliver Rosen,Ying Su,Rodrigo Ruiz-Soto,Michael S. Gordon,Suzanne George +15 more
TL;DR: Ripretinib is a well-tolerated, novel inhibitor of KIT and PDGFRA mutant kinases with promising activity in patients with refractory advanced GIST.
Journal ArticleDOI
ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).
William D. Tap,Andrew J. Wagner,Zsuzsanna Papai,Kristen N. Ganjoo,Chueh-Chuan Yen,Patrick Schöffski,Albiruni Ryan Abdul Razak,Javier Martin Broto,Alexander I. Spira,Akira Kawai,Anders Krarup-Hansen,Axel Le Cesne,Brian A. Van Tine,Yoichi Naito,Se Hoon Park,Victoria Soldatenkova,Gary Mo,Ashwin Shahir,Jennifer Wright,Robin L. Jones +19 more
TL;DR: Olaratumab (a human IgG1 antibody targeting PDGFRα) + dox improved overall survival (OS) and progression-free survival (PFS) vs dox in a Ph 2 trial.
Journal ArticleDOI
Immunotherapy in soft-tissue sarcoma.
TL;DR: A targeted review of the published data and ongoing clinical trials for immunotherapies in patients with sarcoma, which comprise immune checkpoint inhibitors, adoptive cell therapies, and cancer vaccines are presented.
Journal ArticleDOI
Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature.
Christophe Le Tourneau,Albiruni Ryan Abdul Razak,Hui K Gan,Simona Pop,Véronique Diéras,P. Tresca,Xavier Paoletti +6 more
TL;DR: The results do not support a standardisation of the definition of DLT, but the inclusion of following specifications in its definition when relevant would reduce the heterogeneity observed across trials.
Journal ArticleDOI
The Utility of Hedgehog Signaling Pathway Inhibition for Cancer
TL;DR: Determination of effective Hh inhibitor-based combination regimens and development of correlative biomarkers relevant to this pathway should remain as clear priorities for future research.